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Psoriasisis a chronic condition of the skin characterised by distinctive scaly plaques. The immune system is now thought to play a
major role in the development and pathogenesis of psoriasis with immune cells and cytokines inﬂuencing keratinocyte function.
Keratinocytes in turn, can activate and recruit immune cells leading to a positive feedback loop in disease. Natural Killer (NK)
cells are lymphocytes that are best known for killing virally infected and cancer cells. However, evidence is emerging to support a
role for NK cells in psoriasis. NK cells are found in the inﬂammatory inﬁltrate in psoriatic skin lesions. They can produce a range
of inﬂammatory cytokines, many of which are important in the pathogenesis of psoriasis. Recent genetic studies have identiﬁed a
range of potential molecules relating to NK cell biology that are known to be important in psoriasis. This paper will discuss the
evidence, both cellular and genetic, for NK cell involvement in psoriasis.
1.PsoriasisasanInﬂammatory Disease
Psoriasis is chronic inﬂammatory condition of the skin
with signiﬁcant morbidity, aﬀecting approximately 2% of
the Caucasian population. The most common form of the
disease, responsible for up to 90% of cases, is psoriasis
vulgaris [1] and this paper will primarily deal with this form.
It is characterised by demarcated, red, raised, scaly plaques
that typically manifest on the elbows, knees, and scalp [1,
2]. Psoriasis guttate occurs in about 10% of patients [3]
and displays small, scattered plaques [2, 4]. This form may
develop into psoriasis vulgaris [4]. Pustular psoriasis is an
uncommonformofthedisease consisting ofraisedpus-ﬁlled
bumps and large areas of reddened skin [4]. A proportion
of psoriasis patients will develop psoriatic arthritis (PsA), a
debilitating joint disease [2–4].
Psoriatic skin is marked by increased proliferation of
keratinocytes, the major cell of the outermost layer of
skin, resulting in a thickening of the epidermis. Altered
diﬀerentiation and rapid maturation of keratinocytes is
observed, as is parakeratosis, a process whereby ker-
atinocytes retain their nuclei as they rise into the stra-
tum corneum. The granular layer of the epidermis is
reduced or absent and downward projections of the epi-
dermis, known as rete, become elongated. There is marked
angiogenesis and inﬁltration of immune cells into the skin
[1, 2].
The cause of psoriasis is still unknown although it is
clear that there is a strong genetic component to the disease.
Several immune genes have been associated with psoriasis
with the major histocompatibility complex on chromosome
6 being strongly implicated [5, 6]. Outbreaks of psoriasis can
occur at sites of physical trauma and streptococcal infections
have been particularly linked to psoriasis guttate, perhaps
indicating a role for molecular mimicry [4]. There is some
evidence that psoriasis may be an autoimmune disease;
it shares many characteristics with multiple sclerosis and
diabetes mellitus type 1 [7, 8], but as yet no autoantigens or
self-reactive T-cells have been identiﬁed [6, 9].
There are a host of treatments for psoriasis ranging
from topical creams to systematic drugs and phototherapy.
Many eﬀective treatments act on the immune system with
TNF-α and T-cells being the common targets [2]. As our
understanding of the disease immunopathogenesis expands,
new therapeutic strategies targeting the immune system are
being developed. Recent drugs targeting the IL-12/IL-23
family of cytokines has indicated this as a promising new
treatment pathway for psoriasis [1, 10] and illuminates the
eﬀectiveness of targeting the immune system for treatment
of this disease.2 Journal of Biomedicine and Biotechnology
For much of its history psoriasis was believed to be solely
a disorder of the skin characterised by aberrant keratino-
cyte activity. However, with increased understanding of
the disease, a fundamental role for the immune system
in its pathogenesis and maintenance has been established.
Evidence for immune involvement in the course of psoriasis
arose from several sources. The presence of a large number
of immune cells in psoriatic skin suggested that they play a
part in the disease and the discovery that therapies targeting
the immune system were eﬀective for the treatment of
psoriasis further highlighted its importance. The curing of
psoriasis following bone marrow transplantation from a
healthy donortoapsoriatic host, andthe inverseobservation
of the developmentof psoriasis after transplantation of bone
marrow from a psoriatic donor to a healthy host both
indicated the strong part played by the immune system in
this disease [1].
Although the ﬁeld has moved away from the idea of pso-
riasis being a disease only involving the skin, it is clear that
resident skin cells do play a substantial role. Keratinocytes
are believed to play an important part in the recruitment
and activation of immune cells. Keratinocytes are themselves
capable of producing proinﬂammatory cytokines such as
IL-1, IL-6, and TNF-α, as well as antimicrobial peptides and
chemokines that can stimulate immune cell migration to
the skin [11, 12]. Keratinocytes are also highly responsive to
cytokines secreted from immune cells. These may induce the
development of psoriatic features [2], trigger the expression
of adhesion molecules for immune cells or drive further
production of inﬂammatory cytokines from keratinocytes
[5], thus contributing to maintenance of the disease state.
Vascular endothelial cells in psoriatic skin also possess adhe-
sion molecules such as ICAM-1, VCAM-1, and E-selectin
[2, 5]. These molecules are usually found in the lymph
nodes and allow the adherence of immune cells. Immune
cells resident in the skin may also play an important part in
the disease with some authors suggesting the local immune
response may be suﬃcient for development of lesions [13].
The role of the innate immune system in psoriasis is
increasingly seen as important. Neutrophils are found in the
stratum corneum of psoriatic skin [2]. As these cells are
shortlived (approx 3 days), their sustained presence suggests
that they are continually recruited. Dendritic cells (DCs) are
increased in psoriatic lesions and are believed to contribute
to shaping the T-cell response [1, 2]. DC subsets not usually
found in the skin are also observed. Plasmacytoid DCs are
potent producers of IFN-α,w h i c hi st h o u g h tt ob eak e y
cytokinein triggering lesion development,and myeloid DCs,
with the ability to secrete TNF-α and inducible nitric oxide
synthase, have been also been observed in psoriatic skin [2,
5, 13]. There are increased numbers of mature and activated
DCs in psoriatic lesions [5] implying that these cells may be
stimulating other aspects of the immune response.
Natural killer T (NKTs) cells are a subset of lymphocytes
that bear the T-cell receptor along with classical NK cell
molecules including CD56, CD16, CD161, and CD94 [14,
15]. They have a limited T-cell receptor repertoire and are
activated following recognition of glycolipid presented by
the MHC class-1-like molecule CD1d [11, 14]. Interestingly,
keratinocytesexpress CD1dand its expression is upregulated
in psoriatic skin [16, 17]. It has been shown that NKT
cells cultured with keratinocytes were activated to produce
large amounts of IFN-γ [16, 18]. While additional studies
are required to clarify possible changes in NKT populations
in psoriasis, there is evidence of their increased expression
within psoriatic lesions [14]. Previous data on circulating
NKT cells in psoriasis is conﬂicting, with some authors
observing no diﬀerence [7], while others ﬁnding a reduction
in their numbers in patients relative to controls with this
number increasing following treatment [15]. Evidence from
animal models of psoriasis also implies a role for NKT cells
withsomestudiesreportingtheabilityofthesecellstoinduce
psoriasis in xenografted mice [17–19].
Muchofthework investigating theimmunopathogenesis
of psoriasis focuses on T lymphocytes and their importance
in the disease is widely accepted. Both CD4+ and CD8+
T-cells have been found in lesional skin with CD4 cells
primarily in the dermis and CD8 cells in the epidermis [4, 5,
9]. While initially it was believed that psoriasis was mediated
by IFN-γ-producing type 1 T-cells, it is now thought that the
recently characterised Th17 subset also has a signiﬁcant role
[1, 6]. This subset is noted for the production of IL-17 and
IL-22, two cytokines which are present in psoriatic lesions,
in response to IL-23 [20, 21]. The expression of activation
markers by both CD4+ and CD8+ cells has been observed
and most of the T-cells in psoriatic lesions also express the
memory cell antigen, CD45RO [5]. Interestingly, data from
variable T-cell receptor genes indicates the presence of clonal
T-cell populations within psoriatic lesions. This implies the
selective expansion of T-cells bearing receptors of the same
antigen speciﬁcity. However, as yet no antigen has been
identiﬁed as the trigger for psoriasis. It is postulated that the
observed clonality of T-cells may be due to the presence of
unidentiﬁed pathogen antigens, of a bacterial superantigen,
or of host autoantigens possibly coming into play due to
molecular mimicry [4, 11].
2.A RoleofNK CellsinPsoriasis?
NK cells are lymphocytes that are generally considered to be
part of the innate immune system. They are best known for
their ability to kill virally infected and cancer cells; however,
they also produce a range of cytokines including IFN-γ,
TNF-α,a n dT G F - β. They can be deﬁned phenotypically by
the presence of particular surface antigens: either NKp46 or
CD56+CD3− cells. While the role of NK cells in psoriasis
still remains relatively unstudied, there is mounting evidence
thatthesecellsmaycontributetodisease. Ottaviani etal.[22]
found that the inﬂammatory inﬁltrate into psoriatic skin
consisted of 5–8% cells that expressed the NK cell phenotype
of CD56+CD3−. Most of these were of the CD56bright subset
of NK cells. Thought to represent more immature cells,
CD56bright cells are less cytotoxic and more proﬁcient at
cytokine secretion compared to CD56dim NK cells. The
cells present in the inﬁltrate found by Ottaviani et al. also
expressed the activation antigen, CD69, and produced large
quantities of IFN-γ in vitro in response to IL-2 stimu-
lation. Supernatants from these IL2-stimulated NK cellsJournal of Biomedicine and Biotechnology 3
induced activation of keratinocytes causing upregulation of
MHC class I molecules and induction of the expression of
ICAM1 and HLA-DR receptors. The keratinocytes were also
observed to secrete chemokines that are known to attract
NK cells (CXCL10, CCL5, and CCL20) thereby providing
a mechanism of NK cell recruitment to the skin. Indeed,
receptors for these chemokines were identiﬁed on NK cells
found in psoriatic skin, with high levels of CXCR3 and
CCR5(receptorsforCXCL10and CCL5, resp) and moderate
levels of CCR6 (CCL20 receptor) expressed [22]. In this
study, there were ten patients examined; thus, the results
need validation in other cohorts. In addition, the study
examined cells in lesions but did not compare the ﬁndings
to either uninvolved skin or normal healthy skin. Therefore,
it is unclear as to whether the data represent the phenotype
expected in normal skin or if it represents an altered
phenotype associated with psoriasis. The three chemokine
receptors noted in this study, CXCR3, CCR6, and CCR5
have also been recently identiﬁed as mediators of NK cell
recruitment to the skin in allergic contact dermatitis [23].
In terms of NK chemotaxis to psoriatic skin, evidence has
recently emerged for a role for chemerin which is found in
psoriatic lesions and is known to attract cells expressing the
receptor CMKLR1 [24]. The CD56dim subset has been noted
to express this receptor [25] and migration of these cells in
response to chemerin has been shown [24]. The relevance
of this ﬁnding regarding NK cells in psoriasis remains to be
explored.
In another study, Cameron et al. found increased fre-
quencies of cells expressing CD16 or CD57 antigens in
psoriatic skin lesions compared to either uninvolved skin
or skin from normal healthy individuals [7]. These changes
were found in both epidermal and papillary dermal skin
layers. Neither of these markers is ideal for detecting NK
cells that are more accurately deﬁned by either NKp46 or
a combination of CD56+CD3−. The authors also looked at
cells expressing the NK cell receptors, CD94, and 2DL1,
and found the frequency of cells expressing these elevated
in the papillary dermis but not in other skin layers [7]. In
this study, samples numbers were low (n = 10 patients and
n = 4 normal controls) and would thus beneﬁt from further
investigations.
In addition to directly studying receptors expressed by
NK cells, changes in NK cell ligands in psoriasis can provide
evidence supporting a role for NK cells in the disease as
alterations in ligand expression can directly aﬀect NK cell
function (Figure 1). HLA-G, a nonclassical class I molecule,
is expressed in psoriatic skin lesions but not in healthy skin
[26, 27]. HLA-G is recognised by 2DL4, a member the killer
cell immunoglobulin-like receptors (KIRs) expressed by all
NK cells, and LILRB1, which belongs to a related family
of immunoglobulin-like receptors and also expressed by
human NK cells. The leader sequence of the HLA-G protein
may also be presented by the HLA-E molecule allowing
recognition by another set of receptors found on NK cells,
the CD94/NKG2 dimers [28]. LILRB1 has been found on T-
cells in psoriatic skin lesions [26]; however, whether NK cells
receptors for HLA-G are modulated in psoriasis has yet to be
determined.
Although psoriasis is a skin condition, changes in
peripheral blood NK cells have been reported. A decrease
in circulating NK cells was found in patients with chronic
psoriasis with lower frequency of cells expressing common
NK cell markers CD56, CD16, CD94 and 2DL1 (CD158a)
present. The extent of the decrease in circulating NK cell
numbers did not correlate to the clinical severity of disease
[8]. However, this decrease in peripheral blood NK cell
frequency was not observed in a recent study in patients
with new-onset psoriasis, with levels of 2B4, CD48, NKG2D,
CD16, and CD56 unchanged between patients and healthy
controls [29] or in a study focusing on NK cell chemotaxis
to chemerin where percentages of CD56dimCD16+ and
of CD56brightCD16− in the peripheral blood showed no
diﬀerence between patients and controls [24]. Further to
this, a study primarily investigating a role for NKT cells
in psoriasis utilising multicolour CD56 and CD3 staining,
reported no diﬀerence in the percentage of circulating NK
cells in psoriasis compared to healthy controls [15]. Finally,
preliminary data from our own lab also using multicolour
staining to accurately deﬁne NK cells does not indicate a
diﬀerence in NK cell numbers in the blood of patients
compared to healthy controls (S. Dunphy, data not shown).
Phenotypic diﬀerences have been noted between NK
cells in the blood of psoriasis patients compared to healthy
controls. It was found that psoriatic NK cells had increased
expression of the apoptosis-associated Fas receptor, and
lower expression of CD94 and NKG2A. Cell surface expres-
sions of 2B4, CD48, CD16, NKG2D, and CD56 were
unchanged between patients and healthy controls [29]. Pre-
viousworkhasalsoindicatedthatFasmayhaveanimportant
role in the pathogenesis of psoriasis. While it is best known
for its ability to induce apoptosis following engagement of
Fas ligand (FasL), this receptor is also able to cause the
production of proinﬂammatory cytokines including TNF-α,
a key cytokine in psoriasis. Further evidence for a role for
Fas was provided by Gilhar et al. who showed that SCID
mice that receive grafts of uninvolved psoriatic skin from
patients combined with injection of IL2-stimulated NK cells
developed characteristics of psoriasis, and that the blocking
of the Fas/FasL interaction could prevent these changes [30].
Inadditiontocellsurface receptors,moleculesimportant
in NK cell functions, for example, cytotoxicity, have been
implicated in psoriasis although the data are conﬂicting.
In one study, perforin, a pore-forming protein found in
the cytotoxic granules of NK cells and a key mediator of
cytotoxicity, was expressed at higher levels in the lesional
psoriatic skin relative to uninvolved psoriatic or healthy
control skin [31]. Psoriasis patients also had higher levels
of perforin in their peripheral blood lymphocytes compared
to healthy controls. However, the source of this perforin
does not seem to be circulating NK cells, as no diﬀerence
between the number of CD56+Perforin+ or CD16+Perforin+
cells was observed in psoriasis patients compared to controls
[32]; it seems likely that CTLs are responsible for the
elevated perforin levels. Another study has given evidence
for a role of NK cell-produced perforin in psoriasis, with a
signiﬁcantly higher percentage of CD56+Perforin+ found in












Figure 1: NK cells can interact with keratinocytes through a range
of cell surface receptors. NK cells express cell surface receptors
that regulate their interactions with other cell types including ker-
atinocytes. Among these receptors is the NKG2A/CD94 inhibitory
receptor that recognises and binds to HLA-E on target cells. NK
cellsalsoexpressanumberofactivatingreceptors includingNKG2D
which recognises MICA/B stress antigen and the Fas receptor
which can activate cytokine secretion by NK cells. The activating
KIR receptor 2DS1 (and its inhibitory counterpart, 2DL1) binds
the HLA-Cw6 molecule and HLA-Cw6 is the strongest genetic
association known in psoriasis. There is evidence in the literature
to suggest that these receptors play a role in psoriasis. Activated NK
cells are triggered to release their cytotoxic granule contents which
contain perforin and granzymes.
thosewithmildpsoriasis,butinterestinglythisdiﬀerencewas
not observed comparing individuals with severe psoriasis to
healthy controls. It was also noted that the vast majority of
blood cells expressing CD16 were also positive for perforin
in those with severe disease while a signiﬁcantly lower
frequency of CD16 positive cells coexpressing perforin was
found in patients with mild psoriasis [33]. Cells expressing
granzyme B, a serine protease that is released from NK cell
granules and that triggers DNA degradation in target cells,





Cytokines are small soluble proteins that are secreted from
cells and inﬂuence many aspects of cell biology including
proliferation, diﬀerentiation, and activation. They are key
immunological regulators and altered cytokine proﬁles have
been implicated in a host of diseases. Many studies have
conclusively demonstrated that cytokines play an important
role in the pathogenesis of psoriasis. Several of these
cytokines are important in NK cell biology.
IL-12 is a key cytokine in the proliferation and activation
of both NK and T-cells. It triggers the production of the
proinﬂammatory cytokines TNF-α and IFN-γ from these
cells and promotes the development of Th1 type eﬀector T-
cells [12]. IL-12 is a heterodimeric cytokine composed of a
p35 subunit and a p40 subunit which come together to form
a7 0k D ap r o t e i n[ 34]. This p70 protein has been found in
increased levels in psoriatic lesions. The p40 subunit has also
been implicated in psoriasis but current evidence suggests
that this may be due to its presence as part of IL-23, a related
cytokine. No diﬀerences have yet been observed concerning
the p35 subunit. There are conﬂicting reports regarding
the levels of IL-12 in the serum of psoriasis patients, with
some authors ﬁnding decreased levels while others report no
change compared to healthy controls [12].
IL-23 is a proinﬂammatory cytokine with emerging links
to autoimmunity [10]. It is a member of the IL-12 cytokine
family and consists of a unique p19 subunit, and a p40
s u b u n i tt h a ti ts h a r e sw i t hI L - 1 2[ 10, 34]. It is produced
by activated macrophages and dendritic cells [34]a n di s
involved in the development of Th17 cells [35]. The Th17
subset ofCD4+ T-cellshavebeenidentiﬁedasimportantcells
in autoimmune diseases and IL-23 is thought to enhance
secretion of both IL-22 and IL-17 from these cells [20].
IL-23 is also key in stimulating secretion of IL-22 from
NK22 cells (discussed later in review). Memory T-cells are
also stimulated to secrete IFN-γ by IL-23 [12, 36]. Genetic
associations strongly support a role for IL-23 in psoriasis
(see section below). In addition, IL-23 is highly expressed in
lesional psoriatic skin and the expression of both subunits
is signiﬁcantly higher in lesions compared to normal skin
[12].It has beendemonstrated that keratinocytesare capable
of IL-23 production and that IL-23 expression is enhanced
in keratinocytes of psoriatic patients [36]. Furthermore,
therapies that target blocking of IL-23 have been shown to
be eﬀective in the treatment of psoriasis [10, 12].
Another key cytokine is IL-15 which is important for
NK cell development, survival, and activation. It also acts to
sustain inﬂammatory responses, promote angiogenesis, and
suppress apoptosis [12] .I th a sb e e ns h o w nt ot r i g g e rt h e
production of IFN-γ,T N F - α,a n dI L - 1 7[ 37]. Keratinocytes
have been shown to express IL-15 and its unique receptor
subunit, the IL-15R α-chain, on their cell surface. It has been
demonstrated thatIL-15 is capableof inhibiting keratinocyte
apoptosis;thismayberelevantinpsoriasiswhereabnormally
lowlevelsofapoptosisaredisplayed.IL-15ishighlyexpressed
in psoriatic lesions compared to normal skin, as are binding
sites for this cytokine [38]. Further evidence of a role for
IL-15 in psoriasis is supplied by the observation that an
antibody which interferes with IL-15R binding alleviated
psoriasis in a mouse model of the disease [37].
Also important is IL-18 cytokine. It is produced in the
immune response to pathogens and works together with
IL-12 to drive IFN-γ productionfrom NK and T-cells. It also
stimulates the production of IL-13 and IL-4 from cells of the
innate and adaptive immune response including NK cells, T-
cells, basophils, and mast cells. IL-18 is thought to help drive
inﬂammation in psoriasis. Lesional psoriatic skin contains
higher levels of IL-18 mRNA compared to nonlesional or
healthy skin, and increased expression of IL-18 is found in
both involved and uninvolved psoriatic skin compared to
healthy controls. Increased IL-18 has also been reported in
plasma from psoriatic patients compared to healthy controls
[12].
IL-22 is a member of the IL-10 family of cytokines
[20, 39, 40]. It is produced by Th1 and Th17 cells [21, 39].Journal of Biomedicine and Biotechnology 5
Recently, a novel population of NK cells, named NK22 cells,
have been shown to secrete IL-22 [41]. IL-22 has a protective
role at mucosal sites but has also been seen to be detrimental
in autoimmune diseases by promoting inﬂammation [40].
The IL-22 receptorisexpressed onkeratinocytes[21, 39]an d
this cytokine has been shown to trigger keratinocyteproduc-
tion of several antimicrobial proteins, such as β-defensin 2,
which haveheightenedlevelsinpsoriasis [21].Elevatedlevels
of IL-22 mRNA have been reported in psoriatic lesions.
Levels of IL-22 cytokine in the blood have been shown to be
higherin psoriasis patientsandcytokinelevelcorrelatedwith
the disease severity [39]. Ex vivo treatment of keratinocytes
with IL-22 results in the development of psoriatic features
including hyperplasia, parakeratosis, downward epidermal
projections, and acanthosis [21]. Importantly, IL-22 causes
psoriasis-like skin changes in IL-22 transgenic mice; this
eﬀect was enhanced by TNF-α, a key cytokine in psoriasis
[39].
IFN-γ is a cytokine that plays a large number of roles
in the immune response. It is secreted by NK cells and T-
cells [42] and stimulates the release of numerous proinﬂam-
matory cytokines from various cell types. It has roles in
the activation, growth, and diﬀerentiation of lymphocytes
and stimulates the cytotoxic activities of NK cells, CTLs,
and macrophages. Studies on serum levels of IFN-γ in
psoriasis have yielded conﬂicting results, with some authors
noting no change relative to healthy controls. However, there
have also been reports of highly elevated levels of IFN-γ
in the serum and blister ﬂuid of patients; levels correlated
with disease severity and decreased after treatment. Studies
investigating IFN-γ levels in the skin also vary with some
reports observing stronger expression of IFN-γ in both
involved and uninvolved psoriatic skin than in the skin of
healthy controls [12].
TNF-α is produced by a variety of cells including NK
cells[43].TNF-αhas amassed substantialinterest inpsoriasis
whereitappearstobeakeymediatoroftheproinﬂammatory
cascade. TNF-α appears to be locally produced in psoriatic
lesions and its synthesis has been reported to be increased
in involved psoriatic skin compared to uninvolved or healthy
skin. Expression of the TNF receptor 1 is altered in lesional
skin and soluble receptor is also found in higher levels
in the blood of psoriatic patients. Several studies have
found increased levels of TNF-α in the serum of psoriasis
patients with a positive correlation to disease severity noted.
Peripheral blood mononuclear cells isolated from patients
showed increased capacity for TNF-α production in vitro.
TNF-α is the most widely studied and utilized target for
anticytokine psoriasis therapies and several antibodies that
interfere with its functions including etanercept, inﬂiximab
and adalimumab are all highly eﬀective in the treatment of
psoriasis [12].
It is clear that many cytokines known to be important in
psoriasis have strong links with NK biology and are either
produced by NK cells (IFN-γ,T N F - α, and IL-22) or are
important in their activation (IL-15, IL-18, IL-12, and IL-
23). The nature of the relationship between these NK cell




Analysis of psoriasis among twins supports that there is a
strong genetic basis for the development of psoriasis. In
Northern Europeans, the rate of concordance is approxi-
mately 72% among monozygotic twins compared to approx-
imately 15–23% of dizygotic twins. In other populations,
the trend is similar although the percentages diﬀer [44–46].
However, identiﬁcation of the genetic loci involved has not
been straightforward. It is clear that no one genetic locus
causes psoriasis but rather several loci may contribute to the
phenotype of psoriasis. Thus, psoriasis is a complex genetic
disease. Early studies examined a role for MHC genes (HLA
in human) and identiﬁed HLA-Cw6 as a locus associated
with psoriasis [47]. There have been approximately ten
genomewide linkage scans performed and over 20 possible
regions linked to psoriasis identiﬁed; however, many of these
associationsidentiﬁedhavenotbeenreplicatedinotherstud-
ies[48].Morerecently,severalgenomewideassociation scans
(GWASs) have been performed and they have identiﬁed
many genes important in the development and pathogenesis
of psoriasis. A GWAS is a modern genetic tool that scans the
entire genome at deﬁned single nucleotide polymorphisms
(SNPs). These are compared between control and disease
groups, and genetic markers that have an altered frequency
in disease can be identiﬁed. Sometimes the SNPs are located
within known genes and thus a putative functional role for
that gene in disease can be predicted. However, some of the
SNPs reside outside genes and thus act as a marker for genes
in that area. Identiﬁcation of a SNP does not necessarily
identify a gene of interest but rather it identiﬁes an area of
a chromosome that contains a gene that contributes to the
phenotype.
Studies in both Asian and European populations have
been performed and several loci have been conﬁrmed as
important in psoriasis. The most signiﬁcant association
has been with the MHC class I region of chromosome 6
that includes HLA-A, -B, -C, and HLA-E genes [6, 49].
Data suggest that the SNPs associated with psoriasis in this
region are closest to HLA-C gene and further analysis at
the allele level suggested that associated SNP alleles strongly
correlate with HLA-Cw6, conﬁrming the original candidate
gene genetic studies [50]. There are three other genes in
this HLA class I region that have well-deﬁned roles in NK
cell biology: HLA-B, HLA-E, and MICA. HLA-B genes that
encode for a Bw4 epitope provide ligands for a KIR receptor
called KIR3DL1. Indeed, a haplotype containing HLA-B∗57
(HLA-Bw4) has previously been implicated with psoriasis
[51]. HLA-E is a nonclassical class I molecule that provides
a ligand for NKG2A/CD94, and NKG2C/CD94 receptors
expressed by NK cells, and MICA encodes an antigen
expressed in response to stress or particular pathological
situations that activates NK cells through ligation of NKG2D
[52]. An allele of MICA that possibly encodes for a soluble
receptor, termed MICA A5.1, is associated with an increased
risk of Psoriasis Vulgaris in a Chinese patient cohort [53].
Although there has been some controversy in the literature
[6, 54], it seems likely that HLA-Cw6 constitutes the actual6 Journal of Biomedicine and Biotechnology
r i s kv a r i a n tr a t h e rt h a na c t i n ga sam a r k e rf o ran e a r b yg e n e
that is responsible for the eﬀects seen. HLA-C is particularly
interesting from an NK cell perspective as all HLA-C alleles
encode ligands for KIR expressed by NK cells [55].
Several loci outside of the MHC region have also been
implicated in psoriasis. Some of these encode for molecules
involvedin skin and tissue functions, for example, within the
epidermal diﬀerentiation complex, but many of them have
known functions within the immune system. Among these
are cytokines, defence molecules, and immune signalling
components and regulators. These have been described
in detail elsewhere [6, 35, 56] and this paper will focus
only on those that relate to NK cells. The IL-12B gene
that encodes the p40 subunit of both IL-12 and IL-23
has been identiﬁed by GWAS and replicates a previous
candidategeneassociationstudyintheJapanese[57,58].The
IL-23A gene encoding for the p19 subunit of IL-23 is also
associated with psoriasis [59]. These p19 and p40 subunits
combinetogenerateIL-23cytokinethatisknowntopromote
diﬀerentiation of specialised T-cell (Th17) and NK cell
(NK22) subsets [40]. Given that the IL-23R gene (receptor
forIL-23)alsoassociates withpsoriasis, it seemsthat IL-12or
more likely, IL-23, plays a role in psoriasis. The role of IL-12
in NK cell biology is well established. It is known to activate
NK cell functions, for example, cytotoxicity and promote
secretion of IFN-γ [60]. A role for IL-23 has recently been
shown in the generation of the novel NK cell subset, NK22
cells, that appear to have specialised functions in mucosal
sites within the body [40, 61]. Two other loci (TNFAIP3 and
TNIP1) identiﬁed by GWAS inﬂuence immune signalling
[59]. It is thought that these gene products combine to
inhibit NFκB signalling that is an important component in
keratinocyte proliferation and diﬀerentiation in psoriasis.
These molecules inhibit both TNF and Toll-like receptor
signalling pathways.
5.RoleofNK Cell ReceptorsinPsoriasis
The KIR genes are a family of genes found on human
chromosome 19q13.4 [55]. They encode for membrane
bound receptors that are expressed by NK cells and a subset
of T-cells. These receptors interact with HLA class I antigen
expressed on the surface of all nucleated cells. Some of
the KIR receptors activate NK cells upon interactions with
ligand and others inhibit NK cell functions. The activating
receptors (termed 2DS or 3DS KIR) lack a functioning
cytoplasmic tail but rather associate with adaptor molecules
that transduce a positive signal to NK cells. In contrast, the
inhibitory receptors (termed 2DLor 3DLKIR)haveinherent
inhibitory signalling capacity through Immuno Tyrosine-
based Inhibitory Motifs (ITIMs) in their cytoplasmic tails.
KIR haplotypes vary in terms of gene number, gene content,
and allelic polymorphism such that there is huge genetic
variation even within closely related ethnic groups [55, 62].
Signiﬁcant progress has been made in terms of molecular
typing to the extent that all genes can be identiﬁed by
relatively straightforward PCR-SSP reactions [63]. However,
studying the cellular expression and functions of these
r e c e p t o r si sm o r ed i ﬃc u l td u et ot h ef a c tt h a tt h e ya r e
clonally expressed (i.e., individual NK cells will express
diﬀerent combinations of the KIR genes encoded for in their
chromosomes) and that speciﬁc antibodies to individual
KIR receptors have been diﬃcult to generate given the
high sequence similarities of receptors in their extracellular
domains. Thus genetic analysis of KIR genes far supersedes
our understanding of their biology [64].
HLA class I ligands for many of the KIR receptors have
been described. Unlike the TCR that recognises individual
alleles of HLA class I antigen (though the process of
positive selection during development), NK cell receptors
have evolved to recognise conserved epitopes of HLA class I
receptors. Recognition of HLA-C by NK cells is particularly
important as every HLA-C allele contains a motif recognised
by a KIR receptor: HLA-C1 alleles have an NxxK motif
at residues 77–80 of the α1h e a v yc h a i nt h a tp r o v i d e sa n
epitoperecognisedby2DL2,2DL3,and2DS2receptorswhile
HLA-C2 alleles have an SxxN motif at this same region
that is recognised by 2DL1 and 2DS1 KIR receptors [55].
More recently this relatively straightforward delineation of
speciﬁcities has blurred with the recognition that the 2DL2
receptor (that recognises HLA-C1) also weakly recognises
HLA-C2 [65]. A subset of HLA-B genes encode a serological
epitope termed Bw4 that provides a ligand for the 3DL1
and possibly the 3DS1 receptor [66]. Recognition of HLA-A
gene products is diﬀerent as it appears that a particular KIR
receptor, 3DL2, has evolved to recognise individual HLA-A
alleles (A3 and A11) and recognition is peptide dependent
[67].
While HLA class I ligands for some activating KIR have
been described as mentioned above, binding aﬃnity of
activating KIR for HLA class I is generally weaker than that
of the inhibitory receptors. Recently, a systematic search of
HLA class I allotypes for 2DS3, 2DS5 interactions failed to
identify a ligand [68]. Together these facts have resulted in
a growing consensus that perhaps HLA class I is not the
primary ligand for activating KIR receptors. Possible ligands
could include pathogen encoded molecules or endogenous
molecules expressed under pathogenic conditions.
Molecular typing methods have provided tools for KIR
gene association studies. KIR genes are good candidates for
genetic associations with disease for a number of reasons:
(1) genes of the immune system are often associated with
the development or pathogenesis of disease; (2) KIR genes
are polygenic and highly polymorphic; (3) KIR proteins
interact with HLA class I gene products and HLA class I
genes consistently provide the strongest associations with
particular disease. KIR genes have been associated with
the development or progression of disease in a number of
clinical situations including infections, for example, HIV
[69] and HCV infections [70] and noninfectious conditions,
for example, recurrent miscarriage [71, 72]. It has become
clear that the eﬀects of KIR genes on disease may be
subtle and may only manifest in the presence of cognate
HLA class I ligand. As KIR genes and HLA class I genes
segregate on diﬀerent chromosomes, their presence together
is relatively random. Thus disease association studies often
need to investigate both KIR genes and HLA class I genes for












Figure 2: Subsets of NK cells secrete distinct cytokine proﬁles.
Conventional NK cells, consisting of CD56bright and CD56dim
subsets, are found in the general blood circulation. They are
responsive to cytokines, with IL-2, IL-12, IL-15, and IL-18 being
viewed as most important. These cytokines, some of which may
act alone while others are only eﬀective in as part of a milieu,
activate eﬀector functions such as secretion of cytokines including
IFN-γ and TNF-α and degranulation of cytotoxic granules. In
contrast, NK22 cells are a recently described subset of NK cells
that are primarily resident in mucosal sites within the body. They
diﬀerentiate towards the NK22 phenotype in response to IL-23
stimulation. NK22 cells secrete IL-22 cytokine (but not IL-17). IL-
22 is known to be pathogenic in psoriasis.
Several studies have looked for KIR gene associations
with the development of psoriasis and these have mainly
focussed on Psoriasis Vulgaris. However, the data emerging
donotprovide a clearconsensuswith some studiesreporting
a signiﬁcant association of 2DS1 with the development of
disease while others ﬁnd no KIR gene association. For the
studies that did ﬁnd a KIR gene association, 2DS1 has
consistently been identiﬁed as an important locus. In brief,
no KIR gene associations have been found in either Chinese
[73] or US Caucasians [74]. Our preliminary analyses
support these studies with no individual KIR gene associated
with the development of psoriasis in an Irish cohort (S.
Dunphy, data not shown). 2DS1 has been associated with
the development of psoriasis is Swedish [75], Polish [76]
and Japanese patients [77]. In the Japanese study, 2DL5
was also associated with the development of psoriasis. As
the populations studied to date come from a variety of
ethnic backgrounds, this is unlikely to account for the
diﬀerences observed. Another factor to be considered is
the size of the cohorts examined in terms of statistical
power to demonstrate a result. The studies cited range from
96 patients and 50 controls at the lower end (Japanese
cohort) to 237 patient and 372 controls at the higher end
(Swedish cohort) and thus sample size may also contribute
to diﬀerencesseen. The frequencyof2DS1withinthecontrol
populations varies and this will also impact the ability to
identify a role for 2DS1 is psoriasis. Therefore, additional
highly powered studiesare neededto resolvethe roleof2DS1
in the development of psoriasis. However, it is interesting
that the three studies that found a KIR gene association
with psoriasis all identiﬁed 2DS1 as a locus of interest.
2DS1 is particularly attractive in this context as it is the
only activating KIR receptor that has been shown to interact
with HLA-Cw6 [68], which as previously mentioned, is
the strongest genetic susceptibility locus identiﬁed to date
in the development of psoriasis. A functional interaction
between 2DS1 and HLA-Cw6 receptors may provide a
biological rationale for NK cell involvement in psoriasis and
thus, conﬁrmation of 2DS1 as a susceptibility locus, is an
importantresearch questionforNKcellbiologists.Itisworth
noting that even if 2DS1 is conﬁrmed other studies, the
natureofKIRgenehaplotypestructuremeansthat2DS1may
be functioning as a marker for another nearby locus that is
mediating the biological eﬀect.
Psoriatic arthritis is a form of severe arthritis found in a
subset of patients with psoriasis. The ﬁrst study published
on KIR genes in PsA identiﬁed two activating KIR genes,
2DS1and 2DS2 associated with the developmentof psoriatic
arthritis but only in the absence of their cognate HLA-C
ligands in a US cohort [78]. The revised model proposed
by the authors suggested that increasing susceptibility to
psoriatic arthritis was determined by presence of more
activating KIR genotypes (i.e., presence of activating KIR or
lack ofinhibitory KIR,in presence ofligand) [79]. A Swedish
cohort found a trend for 2DS1 involvement in psoriatic
arthritis but it did not reach statistical signiﬁcance [75].
Finally, a second US cohort identiﬁed 2DS1 as a risk factor
for the development of psoriatic arthritis among patients
with psoriasis; however, numbers of patients in this analysis
were low [74]. A single study looking at KIR genes in
guttate psoriasis found no signiﬁcant gene associations with
development of disease [75].
Although GWAS studies have successfully identiﬁed
many loci involved in psoriasis, it is clear that much of the
genetic contribution to psoriasis remains to be identiﬁed.
KIR genes may be among the “missing” genetic risk loci as
it is unlikely that they would be identiﬁed on a genomewide
scan of SNPs, given their complex haplotype variability and
polymorphic nature.
6.FutureAreasofResearch
While there is evidence emerging to support a role for NK
cells in psoriasis, more work needs to be done before we
have a clearer picture of what that actual role might be.
One issue that complicates this question is the variety of
clinical patients cohorts that have been examined in the
context of NK cells. Some groups have studied new onset
Psoriasis Vulgaris while others look at guttate psoriasis, PsA8 Journal of Biomedicine and Biotechnology
or the eﬀect of treatment for psoriasis on NK cell function.
While some of the KIR studies replicate an association
of the 2DS1 gene with psoriasis, others have failed to
do so. Thus, additional cohorts with adequate numbers
and statistical power to address the relevance of this are
required. In general, few of the studies in the literature have
been replicated in other cohorts which makes it diﬃcult
to assess the overall role of NK cells in psoriasis. The ﬁeld
would greatly beneﬁt from some basic NK cell studies in
well-deﬁned and characterised cohorts that have adequate
numbers to conﬁrm basic ﬁndings to date.
However, evidence from large GWAS studies and cell-
based experimental systems have identiﬁed many potential
molecules involved with NK cell biology that are associated
with psoriasis including IL-12 and IL-23. Such analysis may
lead to new exciting avenues of research, for example, a
possible role for NK22 cells in psoriasis. From the GWAS
studies, IL-23 is known to be important in psoriasis [57].
As previously described, it is the key cytokine responsible for
the diﬀerentiation of the NK22 cell type that secretes IL-22
but not IL-17 cytokine (Figure 2)[ 40, 61]. NK22 cells are
not found in peripheral blood but rather in mucosal/tissue
sites within the body. It is tempting to speculate a role for
NK22cellsparticularly as IL-22 is known to be pathogenicin
psoriasis. One could envision a dynamic interaction between
NK cells that are localised to the skin by their chemokine
receptor expression patterns and that diﬀerentiate towards
N K 2 2c e l l si nt h ep r e s e n c eo fI L - 2 3c y t o k i n et h a ti ss e c r e t e d
by keratinocytes. The NK22 cells could then secrete IL-22
which mediates its pathogenic eﬀects. Alternatively, NK cells
recruited to the skin may exhibit a more conventional NK
cell phenotype and secrete IFN-γ and TNF-α that are known
to play a role in psoriasis. If NK cells are involved, and
much evidence supports that they are, it is as yet impossible
to predict how these events are coordinated. Are NK cells
normally resident in the skin activated to secrete factors that
activate keratinocytes, or do activated keratinocytes recruit
NK cells to the skin and activate them to secrete cytokines?
Do both cell types participate in a positive feedback loop?
In summary, evidence is emerging to support a role for NK
cells in psoriasis but this ﬁeld is in relative infancy compared
to studies on other immune cells, for example, T-cells. More
basic studies are required but early indications are that such
studieswill befruitful andrevealnew molecularmechanisms
for NK cell involvement with initiation and progression of
psoriasis.
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